ROCHESTER, MI--(Marketwired - Jul 30, 2013) - OPTIMIZERx Corp. (
HealthTronics, a part of Endo Health Solutions, is a urology solutions company built by urologists to deliver better patient care, better economics, and better outcomes. The HealthTronics EHR solutions were designed by practicing urologists to optimize patient care, while serving the specific needs of urology health professionals.
"We are extremely pleased to be able to partner with HealthTronics to deliver SampleMD's eCoupon and eVoucher solutions to HealthTronics' urologist members, right within their e-Prescribing workflow," said Shad Stastney, Chairman and CEO of OptimizeRx. "By making the ever-increasing menu of urology-focused treatments more affordable for patients, the SampleMD solution improves adherence and outcomes, while at the same time offering important value for our pharmaceutical and EHR clients."
The SampleMD solution will be integrated within the HealthTronics UroChartEHR and meridianEMR solutions.
For more information, please go to www.samplemd.com or contact us at 248-651-6568.
About OptimizeRx Corp
OPTIMIZERx Corp. (
This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended and such section 21E of the Securities Act of 1934, amended. These forward-looking statements should not be used to make an investment decision. The words 'estimate,' 'possible' and 'seeking' and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.